Patent ID: 8394418

Claim:
A composition comprising a combination of: (a) a bile-derived composition comprising small molecular weight components of less than 3000 daltons, and having the following properties: (i) is extracted from bile of animals; (ii) is capable of stimulating monocytes and/or macrophages; (iii) is capable of modulating tumor necrosis factor production and/or release; (iv) contains no measurable level of IL-1α, IL-1β, TNF, IL-6, IL-8, IL-4, GM-CSF or IFN-gamma; (v) is not cytotoxic to human peripheral blood mononuclear cells; and (vi) is not an endotoxin; and (b) at least one chemotherapeutic drug, wherein said composition has an improved efficacy in the treatment of cancer over treatment with the bile-derived composition alone and over treatment with the at least one chemotherapeutic drug alone, or wherein said composition improves the therapeutic index in the treatment of cancer over the bile-derived composition or the at least one chemotherapeutic drug alone, wherein the cancer is selected from the group consisting of melanoma, breast cancer, ovarian cancer and lung cancer; wherein when the cancer is melanoma, the at least one chemotherapeutic drug is dacarbazine; wherein when the cancer is breast cancer, the at least one chemotherapeutic drug is paclitaxel (Taxol); wherein when the cancer is ovarian cancer, the at least one chemotherapeutic drug is cisplatin or paclitaxel (Taxol); and wherein when the cancer is lung cancer, the at least one chemotherapeutic drug is docetaxel (Taxotere).